Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids + gabapentin
- Development stage
- Unknown
- Lead developer
- Ain Shams University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omega-3 fatty acids + gabapentin refers to a therapeutic comparison and potential combination regimen studied by Ain Shams University for the management of uremic pruritus in patients undergoing hemodialysis. Omega-3 fatty acids exert anti-inflammatory effects by competing with arachidonic acid, thereby reducing the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2). Gabapentin is an anticonvulsant that binds to the alpha-2/delta-1 subunit of voltage-gated calcium channels, which is thought to modulate the neuropathic components of uremic itch. In clinical trials, these agents have been evaluated for their ability to reduce itch severity, with omega-3 specifically showing a significant impact on systemic inflammatory markers associated with end-stage renal disease.
- Other names
- omega 3 fatty acid + gabapentin-Ain Shams University-uremic pruritusOmega-3 vs Gabapentin for Uremic PruritusOmega3 vs Gabapentin for Uremic PruritusOmega 3 vs Gabapentin for Uremic Pruritus
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on omega-3 fatty acids + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3 fatty acids + gabapentin.